Morgan Stanley
DMRA

Morgan Stanley’s Damora Therapeutics DMRA Stock Holding History

Morgan Stanley’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Buy
119,027
+22,250
+23% +$539K ﹤0.01% 4577
2026
Q1 		$2.51M Buy
96,777
+21,860
+29% +$562K ﹤0.01% 4603
2025
Q4 		$1.72M Buy
+74,917
New +$1.3M ﹤0.01% 4908
2025
Q1 		– Sell
-100
Closed -$465 – 8135
2024
Q4 		$465 Sell
100
-60
-38% -$392 ﹤0.01% 7350
2024
Q3 		$1.94K Buy
160
+40
+33% +$522 ﹤0.01% 7136
2024
Q2 		$1.42K Sell
120
-160
-57% -$2.53K ﹤0.01% 7111
2024
Q1 		$5.46K Buy
+280
New +$4.98K ﹤0.01% 6869
2023
Q4 		– Hold
0
– – – 7806
2023
Q3 		– Hold
0
– – – 7601
2022
Q2 		– Sell
-23
Closed -$1K – 7866
2022
Q1 		$1K Buy
+23
New +$1.29K ﹤0.01% 7841
2021
Q4 		– Hold
0
– – – 8020
2021
Q3 		– Sell
-4
Closed -$1K – 7965
2021
Q2 		$1K Buy
+4
New +$545 ﹤0.01% 7612
2021
Q1 		– Sell
-40
Closed -$13K – 7511
2020
Q4 		$13K Buy
+40
New +$14.9K ﹤0.01% 6564

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Morgan Stanley's DMRA Position: Q2 2026 in Review

Morgan Stanley increased its Damora Therapeutics (DMRA) stake by 23% in Q2 2026, buying an estimated $539K and bringing the position to 119,027 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #4577.

Morgan Stanley first reported a position in DMRA in Q4 2020 and has held it in 10 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Morgan Stanley held 119,027 shares of Damora Therapeutics worth $3.1M as of Q2 2026.
  • Morgan Stanley bought 22,250 Damora Therapeutics shares in Q2 2026, an estimated $539K.
  • Damora Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4577 holding.
  • Morgan Stanley first reported a position in Damora Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.